Small-Cap Catalyst Watch: March 17-21

We've reviewed numerous filings and press releases to highlight the catalysts and conferences for this upcoming week. Dive into our research and remember—staying ahead is key!

The 37th Annual ROTH Conference will be held March 16-18, 2025, at The Laguna Cliffs Marriott in Dana Point, California. The event features 1-on-1 meetings, fireside chats, keynotes, and panels, along with networking, entertainment, and charity events. Around 450 growth-focused companies from sectors like Healthcare, Technology, Consumer, Sustainability, and more will participate, offering investors valuable insights and direct access to executive management.

Companies Attending: HTCR, ODYS, SNYR, LCUT, PMNT, USIO, MBRX, PYPD, SMTK, CURI, BAER, HBIO, MSS, ALVR, PHUN, PPSI, REKR, NVVE, SOAR, GLTO, ALTO, DVLT, TTI, HURA, COCH, PED, PXLW, STXS, CRON, ISPR, MIGI, PODC, XAIR, AIRG, BEAT, CLNN, PSQH, APVO, LGVN, MGRM, BITF, ARBE, ARAY, PLBY, GRO, LTRX, QUBT, FEAM, LINK, DLPN, GOVX, SUNE, PRE, LWLG, RZLV, GCL, OSS, CLRB, PMN, EGAN, HFFG, DTI, FNGR, BLNK, CDZI, IPW, GAIA, USEG, KOPN, CURR, LVO, SRTS, HSDT, REVB, AMPX, VERA, MSAI, MCHX, DERM, BEEP, ATNM

Sidoti Small-Cap Virtual Conference

Wed, Mar 19, 2025 8:30 AM - Thu, Mar 20, 2025 5:00 PM Companies presenting on March 19th: LCUT, DRTS, HFFG, ONDS, CJMB

Stifel 2025 Virtual CNS Forum, March 18-19th, 2025:

Companies presenting on March 19th: VIGL Companies presenting on March 18th: CMPS, VTGN, ABOS, ANRO

NVIDIA's GPU Technology Conference (GTC) 2025 Scheduled for March 17–21, 2025, in San Jose, California, GTC will feature over 1,000 sessions, 2,000 speakers, and nearly 400 exhibitors, focusing on advancements in AI and accelerated computing.

Companies Attending:

BMR > March 17th (Beamr CEO, Sharon Carmel, will present at GTC a session titled: "The Future of Video Compression is AI-Driven")

SES > March 17th (Dr. Hu will deliver a presentation on AI-Accelerated Materials Discovery for Next-Generation Lithium Metal Batteries)

MIGI > March 17-21, 2025 (Mawson CEO and President, Rahul Mewawalla, and members of management will attend the conference)

KeyBanc Capital Markets Healthcare Forum Held virtually on March 18-19, 2025.

Companies Participating:

HBIO > March 19th

RPID > March 19th

LFMD > March 18th

BIO Europe Spring 2025 The Springtime Partnering Event | March 17–19, 2025 | Milan, Italy This event will bring together nearly 4,000 attendees, facilitating relationship building and meetings across the biotechnology and biopharmaceutical industries.

Participating Companies: EDSA GNPX APVO

Oppenheimer 35th Annual Healthcare MedTech & Services Conference Held virtually from March 17–20, 2025.

Companies Participating: CYH > March 18th NMTC > March 19th

The Society of Toxicology (SOT) 64th Annual Meeting and Tox Expo March 16-20, 2025

Companies Participating:

VPRX > NES100 dose range finding toxicity study will be presented

ALZN > Pharmacokinetics of AL001, Lithium Salicylate/L-Proline Co-crystal: A Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1 (BD1), Alzheimer's Disease (AD), Major Depressive Disorder (MDD), and Post-traumatic Stress Disorder (PTSD) - Monday, March 17, 2025

LSI USA '25 Conference Held at the Waldorf Astoria, Monarch Beach, from March 17-21, 2025

Companies Participating: BEAT AMIX > Tuesday, March 18, 2025

2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Held March 16-19, 2025, in Dallas, TX

Companies Presenting:

PEPG > Company will be presenting two oral presentations as well as five posters. CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 Skipping (Wednesday, March 19th) FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1) (Wednesday, March 19th)

DTIL > Will present preclinical data from the PBGENE-DMD program for the treatment of Duchenne muscular dystrophy (DMD). Title: ARCUS-Mediated Excision of Exons 45-55 Leads to Functional Del45-55 Dystrophin and Restoration of Skeletal Muscle Function for the Treatment of DMD (Wednesday, March 19, 2025)

Additional Catalysts for This Week:

NVTS > Will attend APEC 2025 at Atlanta's Georgia World Congress Center, March 16-20, showcasing GaN and SiC advances for AI, EV, and mobile applications. Technical presentations: March 19th. Marketing & Tech Trends: March 20th.

OXBR > Participation in Digital Asset Summit 2025, a leading institutional finance and blockchain event, taking place at Javits Center North in New York from March 18-20, 2025.

AMPX > Amprius will be participating in the International Battery Seminar and Exhibit from March 17-20, 2025. Amprius CTO Dr. Ionel Stefan will present on Tuesday, March 18th, at 12:00 p.m. ET / 9:00 a.m. PT, with a talk titled “Engineering High-Performance Battery Solutions for Electric Mobility.”

AZTR > Chief Operating Officer Travis Whitfill, Ph.D., MPH, will present at the Microbiome Times Partnering Forum in Brussels, Belgium, from March 18-19, 2025. His presentation, titled “Engineered S. Epidermidis for Treating Skin Diseases: Early Clinical Experience in Netherton Syndrome With ATR-12,” is scheduled for Wednesday, March 19th, from 4:25-4:35 pm CET.

SGRP > received a Third Extension of Amended and Restated Commitment Letter for the financing required under the merger agreement with Highwire Capital extending the Commitment Termination Date to March 17, 2025. All other terms and conditions set forth in the Commitment Letter remain unchanged.

TBH > Lavell Juan, co-founder and CEO, and Daniel Leibovich, co-founder and COO, will ring the Nasdaq closing bell on Monday, March 17, 2025, at the Nasdaq MarketSite in Times Square, NYC.

VCIG > In the fast-growing cybersecurity sector, VCI Global has obtained exclusive rights to offer CyberSecure, a military-grade, AI-powered data security solution. It features real-time threat detection, virus defense, data encryption, and multi-channel backup. The online launch is set for March 19, 2025.

INDP > Indaptus CEO Jeffrey Meckler will present at Tribe Public's Webinar and Q&A event, "Keys To The Kingdom: Unlocking The Power Of Your Immune System," on Monday, March 17, 2025, at 9:00 AM Pacific / 12:00 PM Eastern.

FLUX > Mark Barmettler, Senior Director of Engineering at Flux Power, will be a guest on The New Warehouse Podcast at ProMat 2025 in Chicago. The live discussion is scheduled for Monday, March 17, 2025, at 9:55 AM CDT at McCormick Place.

IHRT > The 2025 iHeartRadio Music Awards, hosted by LL COOL J, will air live from Dolby Theatre in Los Angeles on March 17, 8:00-10:00 p.m. ET (PT tape-delayed) on FOX. Performers include Bad Bunny, Billie Eilish, GloRilla, Gracie Abrams, Kenny Chesney, Muni Long, and Nelly. The event will also stream live on iHeartRadio stations and the iHeartRadio app.

SCNX > Scienture LLC submitted an IND in September 2022, followed by an NDA in October 2023, which was accepted for review with a PDUFA date of August 19, 2024. After addressing FDA requests related to CMC, pharmacovigilance, clinical, microbiology, and labeling, the FDA issued a Complete Response Letter focused on CMC. Scienture resubmitted the NDA on September 17, 2024, which was accepted with a new PDUFA date of March 17, 2025.

ANIX > Dr. Pam Garzone, Chief Development Officer of Anixa, will join the Gynecologic and Breast Cancers panel at the ACGT Summit 2025 on March 19-20, 2025, in New York City. She will discuss Anixa's CAR-T therapy for ovarian cancer on March 19, from 11:15 AM – 12:15 PM ET.

CBAT > CBAK Energy will participate in the Jefferies 6th Asia Forum in Hong Kong on Tuesday, March 18, 2025, at 4:00 PM Beijing/Hong Kong Time (3:00 AM U.S. Eastern Time). The company will provide an overview of its corporate strategy and industry outlook, followed by a Q&A session.

DTI > will participate in the Piper Sandler 25th Annual Energy Conference in Las Vegas from March 17-19, 2025. David Johnson, CFO, and Christian Middleton, VP of Finance, will host one-on-one meetings, while Wayne Prejean, CEO, and Jameson Parker, VP of Corporate Development, will also attend.

LTRX > will showcase its leading-edge embedded compute, Industrial IoT (IIoT) and out-of-band management solutions at Embedded Tech India Expo, co-located with Convergence India Expo, being held March 19–21, 2025, in Bharat Mandapam, New Delhi, India.

ANVS > Annovis will participate in the 13th Alzheimer's & Parkinson's Drug Development Summit in Boston, MA, from March 18-20, 2025. On March 19, Maria Maccecchini, Ph.D., Founder and CEO, will present on Phase III Buntanetap data at 3:30 PM EST. She will also join a panel discussing opportunities in Alpha-Synuclein and Parkinson's drug development.

SNAL > Snail Games will showcase an exciting lineup of panels at the 2025 Game Developers Conference (GDC) from March 19-20, 2025, at Booth S1149. On March 19, highlights include a first look at Ark: Survival Evolved's 10-year celebration (10:30 AM - 11:00 AM), a session on creating living worlds in For The Stars (2:00 PM - 2:30 PM), and a discussion of the Bellwright development journey (3:00 PM - 3:30 PM). On March 20, Honeycomb: The World Beyond will present technical challenges in creating the world of Sota7 (10:30 AM - 11:15 AM), followed by a developer journey of Robots at Midnight by Finish Line Games (2:00 PM - 2:45 PM) and Echoes of Elysium by Loric Games (3:00 PM - 3:30 PM).

RR > Richtech Robotics will be exhibiting at ProWein 2025 in Düsseldorf, Germany, from March 16-18, 2025. The Company will be located at Hall 5, Booth 5E46, showcasing its robotics solutions for the wine and spirits industry. This participation aligns with Richtech Robotics' plans for global expansion.

ABOS > Management will participate in webcast fireside chats at two upcoming investor conferences: UBS Virtual CNS Day on Monday, March 17, 2025, at 12:30 p.m. ET, and Stifel Virtual CNS Days on Tuesday, March 18, 2025, at 3:30 p.m. ET.

CLSD > Clearside Biomedical will present key updates on its CLS-AX Wet AMD program at two upcoming events. At The Macula Society 48th Annual Meeting (Feb 12-15, 2025), Dr. Thomas A. Ciulla, Chief Medical Advisor-Retina, will present top-line results from the ODYSSEY Phase 2b study of suprachoroidally administered CLS-AX in participants with neovascular Age-related Macular Degeneration. At the 5th Annual Wet AMD & Diabetic Eye Disease Drug Summit (March 18-20, 2025), Dr. Victor Chong, Chief Medical Officer, will discuss "Transforming wAMD Treatment: Long-Lasting, Flexible Dosing with Suprachoroidal TKI Delivery."

LUCY > Innovative Eyewear will showcase its expanding line of safety-focused smart eyewear solutions for the hardware and construction industries at the National Hardware Show in Las Vegas, NV, from March 18-20, 2025.

MBRX > Has been selected for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium, held from March 16-19, 2025, in Munich, Germany. The presentation is titled "Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML)" and will take place during the Clinical Studies in AML and ALL session.

BMEA > Has been selected for poster and oral presentations, as well as to chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) in Amsterdam, Netherlands, from March 19-22, 2025. Presentation details include oral presentations on COVALENT-111 and Icovamenib on March 20, a poster on COVALENT-111 on March 21, and a symposium on Harnessing Menin Inhibition on March 22.

LDTC > LeddarTech will showcase its solutions and provide immersive live demonstrations of LeddarNavigator at Tech.AD Europe, a leading conference for ADAS and AD technologies. Participants will experience LeddarVision "Full Surround" (LVS-2+) through on-road demonstrations, showcasing the real-time performance of LeddarTech's AI-driven software in complex driving environments. The conference will be held from March 16-18, 2025, at the Hotel Titanic Chaussee, Berlin.

FULC > Consistent with our commitment to transparency, Fulcrum Therapeutics will present data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral Muscular Dystrophy (FSHD) at the 2025 MDA Conference in Dallas, Texas on March 19th, 2025. Topline results were shared in September 2024, and future development activities for the program were suspended.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.